Results of the phase 3 ELOQUENT-2 trial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.